Brekiya (autoinjector) is a drug owned by Amneal Pharmaceuticals Llc. It is protected by 3 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 26, 2039. Details of Brekiya (autoinjector)'s patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11819501 | Parenteral unit dosage form of dihydroergotamine |
Feb, 2039
(12 years from now) | Active |
| US10532049 | Parenteral unit dosage form of dihydroergotamine |
Feb, 2039
(12 years from now) | Active |
| US11304942 | Parenteral unit dosage form of dihydroergotamine |
Feb, 2039
(12 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Brekiya (autoinjector)'s patents.
Latest Legal Activities on Brekiya (autoinjector)'s Patents
Given below is the list of recent legal activities going on the following patents of Brekiya (autoinjector).
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Patent eGrant Notification | 21 Nov, 2023 | US11819501 |
| Recordation of Patent Grant Mailed | 21 Nov, 2023 | US11819501 |
| Recordation of Patent eGrant | 21 Nov, 2023 | US11819501 |
| Email Notification | 21 Nov, 2023 | US11819501 |
| Patent eGrant Notification | 21 Nov, 2023 | US11819501 |
| Patent Issue Date Used in PTA Calculation | 21 Nov, 2023 | US11819501 |
| Email Notification | 02 Nov, 2023 | US11819501 |
| Issue Notification Mailed | 01 Nov, 2023 | US11819501 |
| Dispatch to FDC | 19 Oct, 2023 | US11819501 |
| Issue Fee Payment Received | 16 Oct, 2023 | US11819501 |
US patents provide insights into the exclusivity only within the United States, but
Brekiya (autoinjector) is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Brekiya (autoinjector)'s family patents as well as insights into
ongoing legal events
on those patents.
Brekiya (autoinjector)'s Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Brekiya (autoinjector)'s generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 26, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Brekiya (autoinjector) Generic API suppliers:
Dihydroergotamine Mesylate is the generic name for the brand Brekiya (autoinjector). 11 different companies have already filed for the generic of Brekiya (autoinjector), with Cipla having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Brekiya (autoinjector)'s generic
Alternative Brands for Brekiya (autoinjector)
There are several other brand drugs using the same active ingredient (Dihydroergotamine Mesylate) as Brekiya (autoinjector). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Dihydroergotamine Mesylate, Brekiya (autoinjector)'s active ingredient. Check the complete list of approved generic manufacturers for Brekiya (autoinjector)
About Brekiya (autoinjector)
Brekiya (Autoinjector) is a drug owned by Amneal Pharmaceuticals Llc. Brekiya (Autoinjector) uses Dihydroergotamine Mesylate as an active ingredient. Brekiya (Autoinjector) was launched by Amneal in 2025.
Approval Date:
Brekiya (autoinjector) was approved by FDA for market use on 14 May, 2025.
Active Ingredient:
Brekiya (autoinjector) uses Dihydroergotamine Mesylate as the active ingredient. Check out other Drugs and Companies using Dihydroergotamine Mesylate ingredient
Dosage:
Brekiya (autoinjector) is available in solution form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1MG/ML | SOLUTION | Prescription | SUBCUTANEOUS |